Bills

SJR 29: EpiPen: pricing.

  • Session Year: 2015-2016
  • House: Senate
  • Latest Version Date: 2016-09-09
Version:

This measure would urge the United States Food and Drug Administration to reconsider its denial of approval for generic alternatives to the epinephrine auto-injector EpiPen, would urge the Congress of the United States to investigate the impact that Mylan NVs monopoly has had on price increases for EpiPen, and would urge the Congress and the President of the United States to take action to limit the unrestrained ability of drug manufacturers to increase prices based on what the market can bear.

Discussed in Hearing

Assembly Floor 3MIN
Aug 31, 2016

Assembly Floor

Senate Floor 9MIN
Aug 30, 2016

Senate Floor

View Older Hearings
Authors shown for version:
Chaptered (9/9/2016)